BeOne Medicines Targets $5B–$5.3B Revenue in 2025 as BRUKINSA Drives BTK Growth and Global Expansion

Key Financial Highlights from BeOne Medicines’ Q2 2025 Earnings Call

BeOne Medicines Ltd. (ONC) delivered a strong performance in the second quarter of 2025, showcasing significant revenue growth and improved financial metrics. The company reported total product revenue of $1.3 billion, marking a 41% year-over-year increase. This growth was driven by continued success across all regions, with BRUKINSA, the company’s flagship BTK inhibitor, contributing significantly to the results.

John V. Oyler, CEO of BeOne Medicines, highlighted that BRUKINSA remains the top-selling BTK inhibitor in the U.S. market, with a growing market share and expanding geographic presence. He emphasized that the drug is not only the fastest-growing brand in its class but also the only BTK inhibitor approved for five indications. This leadership position is expected to further strengthen as the company advances its pipeline and expands into new markets.

The CFO, Aaron Rosenberg, noted that BRUKINSA's global revenues reached $950 million in the quarter, reflecting a 49% year-over-year growth. This performance was supported by strong sales in the U.S., China, and Europe. Additionally, gross margin improved to approximately 87%, up from 85% in the previous quarter. Net income for the quarter was $94 million, with diluted earnings per ADS at $0.84. Non-GAAP net income reached $253 million, translating to $2.25 per diluted ADS.

Rosenberg also announced an updated full-year revenue guidance for 2025, now projecting total revenue between $5 billion and $5.3 billion. This upward revision reflects the company’s confidence in its execution and the momentum generated from recent successes.

Pipeline Progress and Future Milestones

Wang Lai, Global Head of R&D, provided insights into the company’s pipeline, stating that BeOne Medicines is at a pivotal moment in its development journey. The company has built robust internal capabilities in research, clinical development, and manufacturing, enabling it to bring novel oncology treatments to market more efficiently than industry standards.

Looking ahead, the company expects several key milestones in the coming years. By the end of 2026, BeOne anticipates initial global approval for sonro and potential pivotal data for its BTK CDAC program. The internal clinical team will be conducting over 20 Phase III trials, with more than 10 proof-of-concept data readouts expected throughout the year.

In addition, the company is advancing multiple programs, including the evaluation of BTK degraders in autoimmune conditions. Wang Lai mentioned that the company is actively exploring different applications for this molecule, signaling potential expansion beyond oncology.

Operational and Strategic Outlook

The company maintained its operating expense guidance for 2025 at $4.1 billion to $4.4 billion. Rosenberg reiterated the company’s commitment to achieving positive GAAP operating income and generating positive free cash flow for the year. Free cash flow for Q2 2025 reached $220 million, underscoring the company’s strong financial position.

Rosenberg also addressed concerns about gross margin improvements, citing enhanced production efficiencies, particularly for TEVIMBRA. He noted that the current guidance already factors in known risks related to U.S. tariffs, with supply chain regionalization efforts helping to mitigate potential impacts.

Analyst Questions and Market Sentiment

Analysts raised several questions during the call, focusing on pricing dynamics, market growth, resistance mechanisms, and the impact of tariffs. While sentiment remained neutral to slightly positive, there was a clear emphasis on understanding future growth drivers and clarifying certain aspects of the business.

Management maintained a confident tone throughout the call, with Oyler expressing confidence in BeOne’s long-term market leadership. Rosenberg emphasized the company’s broad access strategy and protected class status, which ensure that patients have unfettered access to BRUKINSA.

Quarter-over-Quarter Comparison and Competitive Landscape

Compared to the previous quarter, the company showed increased confidence, supported by stronger revenue growth and an upgraded guidance. The 2025 revenue guidance was raised from $4.9 billion–$5.3 billion in Q1 to $5 billion–$5.3 billion in Q2, reflecting improved execution in the first half of the year.

BRUKINSA’s market leadership was reinforced, with growing market share and continued geographic expansion. Management shifted its focus from building foundational capabilities in Q1 to highlighting execution and global leadership in Q2.

Risks and Challenges

Despite the positive outlook, management acknowledged ongoing challenges, including aggressive discounting by competitors and the evolving U.S. tariff environment. However, they emphasized that their broad access strategy and protected class status provide a competitive advantage.

The company continues to monitor potential impacts from U.S. tariffs, but current guidance already factors in known risks. Supply chain regionalization efforts are ongoing to further mitigate any adverse effects.

Final Takeaway

BeOne Medicines demonstrated exceptional execution in Q2 2025, achieving significant revenue and margin growth while raising full-year revenue guidance. The company reinforced BRUKINSA’s leadership in the BTK inhibitor market, highlighted robust global expansion, and advanced its rapidly growing pipeline. Despite challenges such as competitive pricing and regulatory risks, management remains confident in its ability to maintain market leadership and deliver long-term value.